Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial-Reference-Cited by-同舟云学术

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Published:2016-08 Issue:2 Volume:70 Page:256-262
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Gravis Gwenaelle,Boher Jean-Marie,Joly Florence,Soulié Michel,Albiges Laurence,Priou Franck,Latorzeff Igor,Delva Remy,Krakowski Ivan,Laguerre Brigitte,Rolland Frédéric,Théodore Christine,Deplanque Gael,Ferrero Jean-Marc,Culine Stéphane,Mourey Loïc,Beuzeboc Philippe,Habibian Muriel,Oudard Stéphane,Fizazi Karim

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 367 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis;British Journal of Cancer;2024-09-02

2. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

3. Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm;Clinical Genitourinary Cancer;2024-08

4. PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC);Clinical and Translational Oncology;2024-07-29

5. Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis;Holistic Integrative Oncology;2024-07-22